1. Home
  2. Stocks
  3. Lauruslabs Share Price

Laurus Labs Share Price

Pharmaceuticals Large Cap

₹489.25 +1.8 (0.37%)

05 Nov, 2024 17:28

SIP TrendupStart SIP in LAURUSLABS

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹482
  • High
  • ₹494
  • 52 Week Low
  • ₹361
  • 52 Week High
  • ₹518
  • Open Price₹486
  • Previous Close₹487
  • Volume2,564,125

Investment Returns

  • Over 1 Month + 9.91%
  • Over 3 Month + 9.43%
  • Over 6 Month + 9.37%
  • Over 1 Year + 34.3%
SIP Lightning

Smart Investing Starts Here Start SIP with Laurus Labs for Steady Growth!

Laurus Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 201.2
  • PEG Ratio
  • -3.1
  • Market Cap Cr
  • 26,378
  • P/B Ratio
  • 6.4
  • Average True Range
  • 17.34
  • EPS
  • 4.2
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 2.81
  • RSI
  • 56.03
  • MFI
  • 78.38

Laurus Labs Financial

IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations1,184.851,116.931,414.521,132.191,158.03
Total Income From Operations1,184.851,116.931,414.521,132.191,158.03
P/L Before Interest, Excpt. Items & Tax102.7879.69206.3094.26101.01
P/L Before Exceptional Items & Tax58.0938.80164.3156.7063.21
P/L After Tax from Ordinary Activities42.4428.78121.3242.6446.67
Net Profit/Loss For the Period42.4428.78121.3242.6446.67
IndicatorMar 24Mar 23
Revenue From Operations [Gross]4,774.195,742.32
Revenue From Operations [Net]4,774.195,742.32
Total Operating Revenues4,812.395,773.45
Total Revenue4,859.815,789.40
Total Expenses4,558.344,737.97
Profit/Loss Before Tax301.471,051.43
Profit/Loss For The Period223.70760.38
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity658.54881.55
Net Cash Used In Investing Activity-756.74-735.27
Net Cash Used in Finance Activity139.41-185.19
Net Inc/Dec In Cash And Equivalent41.21-38.91
Cash And Equivalent End Of Year42.631.42
IndicatorMar 24Mar 23
Total Share Capital107.79107.73
Total Non-Current Liabilities724.64794.82
Total Current Liabilities2,735.792,106.32
Total Capital And Liabilities7,667.486,957.96
Total Non-Current Assets4,150.373,786.70
Total Current Assets3,517.113,171.26
Total Assets7,667.486,957.96
Indicator20242023
EBIT Margin (%)9.3920.73
Return On Capital Employed (%)9.1724.67
Return On Equity (%)5.3118.74
Long Term Debt To Equity (%)11.6513.93
Book Value/Share (INR)78.0675.31
IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations1,223.701,194.911,439.671,194.921,224.45
Total Income From Operations1,223.701,194.911,439.671,194.921,224.45
P/L Before Interest, Excpt. Items & Tax75.4267.65157.7785.4496.28
P/L Before Exceptional Items & Tax22.8118.46107.2734.6253.89
P/L After Tax from Ordinary Activities17.7212.2175.3225.1739.32
Net Profit/Loss For the Period17.7212.2175.3225.1739.32
IndicatorMar 24Mar 23
Revenue From Operations [Gross]5,001.806,014.22
Revenue From Operations [Net]5,001.806,014.22
Total Operating Revenues5,040.836,040.55
Total Revenue5,067.176,046.55
Total Expenses4,830.814,937.61
Profit/Loss Before Tax236.361,108.94
Profit/Loss For The Period168.21796.64
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity665.69993.90
Net Cash Used In Investing Activity-822.42-996.06
Net Cash Used in Finance Activity249.83-26.64
Net Inc/Dec In Cash And Equivalent93.27-29.68
Cash And Equivalent End Of Year138.9445.67
IndicatorMar 24Mar 23
Total Share Capital107.79107.73
Total Non-Current Liabilities1,159.181,179.48
Total Current Liabilities3,112.282,432.26
Total Capital And Liabilities8,387.037,660.40
Total Non-Current Assets4,552.064,198.72
Total Current Assets3,834.973,461.68
Total Assets8,387.037,660.40
Indicator20242023
EBIT Margin (%)8.3121.09
Return On Capital Employed (%)7.9424.37
Return On Equity (%)3.9019.56
Long Term Debt To Equity (%)19.4118.85
Book Value/Share (INR)76.3675.16

Laurus Labs Technicals

EMA & SMA

Current Price
₹489.25
+ 1.8 (0.37%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹475.77
  • 50 Day
  • ₹468.74
  • 100 Day
  • ₹458.83
  • 200 Day
  • ₹442.21

Resistance and Support

491.17 Pivot Speed
  • R3 516.23
  • R2 509.12
  • R1 498.28
  • S1 480.33
  • S2 473.22
  • S3 462.38

Is Laurus Labs Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Laurus Labs Ltd. is a leading pharmaceutical company specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs), focusing on anti-retrovirals, oncology, and cardiovascular treatments. It also provides contract development and manufacturing (CDMO) services globally. Laurus Labs has an operating revenue of Rs. 5,053.20 Cr. on a trailing 12-month basis. An annual revenue de-growth of -16% needs improvement, Pre-tax margin of 5% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 19%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 5% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 20 which is a POOR score indicating inconsistency in earnings, a RS Rating of 60 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Laurus Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-24 Quarterly Results & Interim Dividend
2024-07-25 Quarterly Results
2024-04-25 Audited Results & Interim Dividend
2024-01-24 Quarterly Results
2023-10-20 Quarterly Results & Interim Dividend
Date Purpose Remarks
2024-11-06 INTERIM Rs.0.40 per share(20%)Interim Dividend
2024-05-08 INTERIM Rs.0.40 per share(20%)Interim Dividend
2023-11-02 INTERIM Rs.0.40 per share(20%)Interim Dividend
2023-05-10 INTERIM Rs.1.20 per share(60%)Interim Dividend
2022-11-04 INTERIM Rs.0.80 per share(40%)Interim Dividend
Date Purpose Remarks
2020-09-30 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.

Laurus Labs F&O

Laurus Labs Shareholding Pattern

27.18%
8.25%
4.06%
26.08%
0%
22.67%
11.76%
  • NSE Symbol
  • LAURUSLABS
  • BSE Symbol
  • 540222
  • ISIN
  • INE947Q01028

Laurus Labs FAQs

Laurus Labs share price is ₹489 As on 05 November, 2024 | 17:14

The Market Cap of Laurus Labs is ₹26378.4 Cr As on 05 November, 2024 | 17:14

The P/E ratio of Laurus Labs is 201.2 As on 05 November, 2024 | 17:14

The PB ratio of Laurus Labs is 6.4 As on 05 November, 2024 | 17:14

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.